Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06608511 · ClinicalTrials.gov registry record
Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
A clinical trial of Skin Cancer and Melanoma (Skin Cancer), sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT06608511: Recruiting study of Skin Cancer and Melanoma (Skin Cancer), sponsored by University of Wisconsin, Madison.
NCT06608511 is a study of Skin Cancer and Melanoma (Skin Cancer) that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 20 participants, below the 464-participant average among 40 other Skin Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06608511, a study of Skin Cancer and Melanoma (Skin Cancer), is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to study blood samples and compare them to other biospecimens and clinical outcomes in participants who have melanoma or non-melanoma skin cancers. The main question it aims to answer is: * Are blood based signatures able to predict progression-free survival (PFS)? Participants undergoing regular treatment for their skin cancer will provide blood samples.
Primary Outcome
To investigate whether changes in tumor-derived exomes measured in serum could represent a potential prognostic biomarker, measured as progression free survival (the duration of time from Day 1 of treatment to time of progression based on clinical or radiographic grounds) or death as a results of any cause, whichever occurs first.
Conditions Studied
Interventions
- OTHER Blood draw for the laboratory assessment
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-12-11 |
| Est. Completion | 2026-12 |
What NCT06608511 shows while recruiting
NCT06608511 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 464-participant average among 40 other Skin Cancer trials with a reported enrollment target (96% lower).
The record links to 6 conditions, with Skin Cancer appearing as the primary indexed condition, and to 1 intervention - of which Blood draw for the laboratory assessment is the first listed.
NCT06608511 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06608511 about?
NCT06608511 is a clinical study titled "Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers". The goal of this observational study is to study blood samples and compare them to other biospecimens and clinical outcomes in participants who have melanoma or non-melanoma skin cancers. The main question it aims to answer is: * Are blood based signatures able to predict progression-free survival ...
What is the current status of trial NCT06608511?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2024-12-11. Estimated completion is 2026-12.
What conditions does trial NCT06608511 study?
This clinical trial studies the following conditions: Skin Cancer, Melanoma (Skin Cancer), Cutaneous Squamous Cell Carcinoma (CSCC), Merkel Cell Carcinoma of Skin, Basal Cell Carcinoma of Skin.
What interventions are being tested in trial NCT06608511?
The interventions under investigation include: Blood draw for the laboratory assessment (OTHER).
Who is sponsoring clinical trial NCT06608511?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06608511 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06608511's enrollment target sits among peer trials
20 37th of 40 higher than 3 of 40 other Skin Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Skin Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rural Adult and Youth Sun Protection Study
RECRUITING · NA
-
TIL Therapy in cSCC and MCC
RECRUITING · Phase 2
-
Undergraduate Skin Cancer Prevention Trial
RECRUITING · Phase 3
-
Meloxicam in Mohs Micrographic Surgery
RECRUITING · Phase 4
-
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
RECRUITING · Phase 1
-
Pilot Trial of Supplemental Vitamin A and Nicotinamide
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI